Organon has recently announced new results from the phase 3 ADORING 3 open-label, long-term extension study evaluating tapinarof cream, 1% (VTAMA), for the treatment of atopic dermatitis (AD). The ...

The study, known as BRAVE-AA-PEDS, was sponsored by Eli Lilly and Company and involved 257 adolescents aged 12 to under 18 years. Baricitinib, an oral Janus kinase (JAK) inhibitor, demonstrated ...

At the 2025 NAPNAP National Conference, Maureen Madden, DNP, CPNP-AC, CCRN, FCCM, FAAN, provides the key takeaways and recommendations for glycemic control guidance, updated in 2024. In this video ...

A presentation at the 46th National Association of Pediatric Nurse Practitioners (NAPNAP) conference explored the role of biologics in pediatric care, their applications in various conditions, and ...

A quick look into some of the top sessions occurring at the NAPNAP National Conference, being held from March 10-13, 2025 in Chicago, IL. The National Association of Pediatric Nurse Practitioners ...

Study: Nearly 80% of infants born in 2023-24 RSV season received RSV protection ...

Lebrikizumab improves itch, sleep interference, and skin pain in atopic dermatitis patients previously treated with dupilumab, offering a new treatment option. A new Phase-3b study has found that ...

Jay T. Rubinstein, MD, PhD, highlighted promising CHORD trial data showing that DB-OTO gene therapy has led to hearing improvements in treated participants. New data from the CHORD trial (NCT05788536) ...

Puzzler poll: Urticarial rash in a 9-hours-old male ...

Over the past decade, there has been an emergence of commercially available home devices to help monitor an infant’s vital signs during sleep. These devices aim to provide reassurance and peace of ...

After 9.5 months, 94% of participants reported an improvement in incontinence symptoms, with 58% experiencing complete resolution and 18 (36%) reporting greater than 50% reduction in the number of ...

The newly-approved indication is for children aged 4 years and older who weigh 33 < 66 lbs, expanding on the August 9, 2024 approval in children at least 66 lbs. As of March 5, 2025, epinephrine nasal ...